Hemogenyx Share Price (HEMO)

Maybe trying to stimulate share price? I’ve never seen such a static stock in 34 stock market years. Suppose the only thing that will change this is news but still, there’s not much range in this one.

(i) to set current context and focus to the report, which is otherwise bias to 2023 and the 31/12/23 position and required disclosures; and

(ii) it's a continuation of the much improved and welcome engagement with shareholders (as a whole) that we started to see in 2023, and this is re-emphasised on page 31 of the Annual Report (but to save people reading teh report to find it):

"The Company is committed to a continuous dialogue with shareholders as it believes that this is essential to ensure a greater understanding of and confidence amongst its shareholders in the medium- and longer- term strategy of the Group and in the Board’s ability to oversee its implementation. It is the responsibility of the Board as a whole to ensure that a satisfactory dialogue takes place."

That said, (as many others have stated they have found previously) I also didn't get 'Proof of Concept' for the statement promulgated on p32 of the Annual Report:

"The Board’s primary shareholder contact is through Peter Redmond, the Non-Executive Director responsible for shareholder relations." - as I too didn't get any response or acknowledgement to my emailed request. But I see that he was in attendance at 12/12 board meetings in 2023 - though I'm not sure that's going to get my vote for re-election at this year's AGM - more needed.

With your critical thinking caps on... Why the interview now?

Https://www.itv.com/news/anglia/2024-04-26/new-drug-which-could-cure-cancer-tested-on-melanoma-patient

Well said Hikikomori.

I guess most of us will topslice some along the way.

Quite frankly, it would be downright silly not to de-risk a portion at some point.

But based on the fantastic information that was released yesterday, I intend on selling as few as I can defend.

As you say, if CBR delivers just a fraction.

Wow

But before then we got CAR-T, news will eventually come, question is will the investors who are willing to pay above today's share price follow?

If they don't, then the share price will stay suppressed, it's a simple question of supply and demand.

Even if the science is first class.

And from what was in the RNS yesterday, I can only conclude that the science is indeed first class.

And that the board is capable of getting funding in a difficult market.

There is a lot to like in my view.